597 related articles for article (PubMed ID: 20556762)
1. Pharmacological interventions for borderline personality disorder.
Stoffers J; Völlm BA; Rücker G; Timmer A; Huband N; Lieb K
Cochrane Database Syst Rev; 2010 Jun; (6):CD005653. PubMed ID: 20556762
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological interventions for people with borderline personality disorder.
Stoffers-Winterling JM; Storebø OJ; Pereira Ribeiro J; Kongerslev MT; Völlm BA; Mattivi JT; Faltinsen E; Todorovac A; Jørgensen MS; Callesen HE; Sales CP; Schaug JP; Simonsen E; Lieb K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD012956. PubMed ID: 36375174
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological interventions for people with borderline personality disorder.
Binks CA; Fenton M; McCarthy L; Lee T; Adams CE; Duggan C
Cochrane Database Syst Rev; 2006 Jan; (1):CD005653. PubMed ID: 16437535
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials.
Lieb K; Völlm B; Rücker G; Timmer A; Stoffers JM
Br J Psychiatry; 2010 Jan; 196(1):4-12. PubMed ID: 20044651
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions for the treatment of disordered and problem gambling.
Dowling N; Merkouris S; Lubman D; Thomas S; Bowden-Jones H; Cowlishaw S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD008936. PubMed ID: 36130734
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of borderline personality disorder: a systematic review for publication purpose.
Bellino S; Rinaldi C; Bozzatello P; Bogetto F
Curr Med Chem; 2011; 18(22):3322-9. PubMed ID: 21728970
[TBL] [Abstract][Full Text] [Related]
7. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
8. Psychological therapies for people with borderline personality disorder.
Stoffers JM; Völlm BA; Rücker G; Timmer A; Huband N; Lieb K
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD005652. PubMed ID: 22895952
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for borderline personality disorder--current evidence and recent trends.
Stoffers JM; Lieb K
Curr Psychiatry Rep; 2015 Jan; 17(1):534. PubMed ID: 25413640
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of pharmacotherapies for borderline personality disorder.
Bellino S; Paradiso E; Bogetto F
CNS Drugs; 2008; 22(8):671-92. PubMed ID: 18601305
[TBL] [Abstract][Full Text] [Related]
11. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
12. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.
Bozzatello P; Rocca P; Uscinska M; Bellino S
CNS Drugs; 2017 Sep; 31(9):809-819. PubMed ID: 28741044
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
15. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis.
Gartlehner G; Crotty K; Kennedy S; Edlund MJ; Ali R; Siddiqui M; Fortman R; Wines R; Persad E; Viswanathan M
CNS Drugs; 2021 Oct; 35(10):1053-1067. PubMed ID: 34495494
[TBL] [Abstract][Full Text] [Related]
18. Lamotrigine for people with borderline personality disorder: a RCT.
Crawford MJ; Sanatinia R; Barrett B; Cunningham G; Dale O; Ganguli P; Lawrence-Smith G; Leeson VC; Lemonsky F; Lykomitrou-Matthews G; Montgomery A; Morriss R; Munjiza J; Paton C; Skorodzien I; Singh V; Tan W; Tyrer P; Reilly JG
Health Technol Assess; 2018 Apr; 22(17):1-68. PubMed ID: 29651981
[TBL] [Abstract][Full Text] [Related]
19. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
Bridle C; Palmer S; Bagnall AM; Darba J; Duffy S; Sculpher M; Riemsma R
Health Technol Assess; 2004 May; 8(19):iii-iv, 1-187. PubMed ID: 15147609
[TBL] [Abstract][Full Text] [Related]
20. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.
Pinto OC; Akiskal HS
J Affect Disord; 1998 Dec; 51(3):333-43. PubMed ID: 10333987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
